<DOC>
	<DOC>NCT01961921</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).</brief_summary>
	<brief_title>The Study of an Investigational Drug, ALN-TTR02 (Patisiran), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Previously received and tolerated ALNTTR02 (patisiran) in Study ALNTTR02002. Adequate Karnofsky performance status, liver function, and renal function. Pregnant or nursing. Has had a liver transplant. Has a New York Heart Association heart failure classification &gt;2. Has unstable angina. Has uncontrolled clinically significant cardiac arrhythmia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>